A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Adriforant (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ZEST Trial
- Sponsors Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 30 Sep 2019 Planned End Date changed from 16 Mar 2020 to 15 Jan 2021.
- 30 Sep 2019 Planned primary completion date changed from 16 Mar 2020 to 18 Dec 2020.
- 26 Mar 2019 Planned End Date changed from 15 Aug 2019 to 16 Mar 2020.